

Fabrizio Schifano

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4396406/fabrizio-schifano-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

99
papers

2,770
citations

29
h-index

49
g-index

118
ext. papers

3,504
ext. citations

4.3
avg, IF

5.93
L-index

#	Paper	IF	Citations
99	Mephedrone (4-methylmethcathinone; 'meow meow'): chemical, pharmacological and clinical issues. <i>Psychopharmacology</i> , 2011 , 214, 593-602	4.7	246
98	Novel psychoactive substances of interest for psychiatry. <i>World Psychiatry</i> , 2015 , 14, 15-26	14.4	211
97	Misuse and abuse of pregabalin and gabapentin: cause for concern?. <i>CNS Drugs</i> , 2014 , 28, 491-6	6.7	148
96	e-Psychonauts: conducting research in online drug forum communities. <i>Journal of Mental Health</i> , 2012 , 21, 386-94	2.7	102
95	A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency's 'Suspected Adverse Drug Reactions' Database. <i>CNS Drugs</i> , 2016 , 30, 647-54	6.7	90
94	Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, "meow meow") in the United Kingdom. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 710-4	1.7	88
93	When "Chems" Meet Sex: A Rising Phenomenon Called "ChemSex". <i>Current Neuropharmacology</i> , 2017 , 15, 762-770	7.6	85
92	25C-NBOMe: preliminary data on pharmacology, psychoactive effects, and toxicity of a new potent and dangerous hallucinogenic drug. <i>BioMed Research International</i> , 2014 , 2014, 734749	3	64
91	Substance use in the club scene of Rome: a pilot study. <i>BioMed Research International</i> , 2014 , 2014, 617546	3.6	64
90	Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. <i>Neuroscience and Biobehavioral Reviews</i> , 2015 , 53, 52-78	9	62
89	Cannabidiol (CBD) use in psychiatric disorders: A systematic review. <i>NeuroToxicology</i> , 2019 , 74, 282-298	4.4	59
88	Native CB1 receptor affinity, intrinsic activity and accumbens shell dopamine stimulant properties of third generation SPICE/K2 cannabinoids: BB-22, 5F-PB-22, 5F-AKB-48 and STS-135. <i>Neuropharmacology</i> , 2016 , 105, 630-638	5.5	56
87	Mind navigators of chemicals' experimenters? A web-based description of e-psychonauts. <i>Cyberpsychology, Behavior, and Social Networking</i> , 2015 , 18, 296-300	4.4	54
86	COVID-19: The Hidden Impact on Mental Health and Drug Addiction. <i>Frontiers in Psychiatry</i> , 2020 , 11, 767	5	51
85	Novel psychoactive substance consumption is more represented in bipolar disorder than in psychotic disorders: A multicenter-observational study. <i>Human Psychopharmacology</i> , 2017 , 32, e2578	2.3	50
84	Personality dimensions and psychopathological profiles of Ecstasy users. <i>Human Psychopharmacology</i> , 2001 , 16, 635-639	2.3	50
83	An international survey on the awareness, use, preference, and health perception of novel psychoactive substances (NPS). <i>Human Psychopharmacology</i> , 2017 , 32, e2581	2.3	49

82	Psychoactive drug or mystical incense? Overview of the online available information on Spice products. <i>International Journal of Culture and Mental Health</i> , 2009 , 2, 137-144		49
81	Monitoring novel psychoactive substances allegedly offered online for sale in Persian and Arabic languages. <i>International Journal of Drug Policy</i> , 2014 , 25, 724-6	5.5	47
80	Profiling online recreational/prescription drugs' customers and overview of drug vending virtual marketplaces. <i>Human Psychopharmacology</i> , 2015 , 30, 302-18	2.3	47
79	The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. <i>Frontiers in Psychiatry</i> , 2017 , 8, 240	5	46
78	An Insight into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. <i>International Journal of Neuropsychopharmacology</i> , 2019 , 22, 270-277	5.8	45
77	Sexual enhancement products for sale online: raising awareness of the psychoactive effects of yohimbine, maca, horny goat weed, and Ginkgo biloba. <i>BioMed Research International</i> , 2014 , 2014, 841798		40
76	Novel psychoactive substances: the pharmacology of stimulants and hallucinogens. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 943-54	3.8	34
75	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. <i>Brain Sciences</i> , 2018 , 8,	3.4	34
74	An insight into the deep web; why it matters for addiction psychiatry?. <i>Human Psychopharmacology</i> , 2017 , 32, e2573	2.3	34
73	Assessing the 2004-2018 Fentanyl Misusing Issues Reported to an International Range of Adverse Reporting Systems. <i>Frontiers in Pharmacology</i> , 2019 , 10, 46	5.6	32
72	Intended and unintended use of cathinone mixtures. <i>Human Psychopharmacology</i> , 2017 , 32, e2598	2.3	32
71	Cocaine/crack cocaine consumption, treatment demand, seizures, related offences, prices, average purity levels and deaths in the UK (1990 - 2004). <i>Journal of Psychopharmacology</i> , 2008 , 22, 71-9	4.6	30
70	The clinical challenges of synthetic cathinones. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 410-419	3.8	29
69	Synthetic Cannabinoid use in a Case Series of Patients with Psychosis Presenting to Acute Psychiatric Settings: Clinical Presentation and Management Issues. <i>Brain Sciences</i> , 2018 , 8,	3.4	26
68	Olanzapine as the ideal "trip terminator"? Analysis of online reports relating to antipsychotics' use and misuse following occurrence of novel psychoactive substance-related psychotic symptoms. <i>Human Psychopharmacology</i> , 2015 , 30, 249-54	2.3	26
67	Herbal Highs: Review on Psychoactive Effects and Neuropharmacology. <i>Current Neuropharmacology</i> , 2017 , 15, 750-761	7.6	25
66	A systematic review of the nature of dispensing errors in hospital pharmacies. <i>Integrated Pharmacy Research & Practice</i> , 2016 , 5, 1-10	4.4	24
65	Bundle of fun or Bunch of problems? Case series of khat-related deaths in the UK. <i>Drugs: Education, Prevention and Policy</i> , 2011 , 18, 408-425	1.2	23

64	Is there such a thing as a 'loper' dope? Analysis of loperamide-related European Medicines Agency (EMA) pharmacovigilance database reports. <i>PLoS ONE</i> , 2018 , 13, e0204443	3.7	22
63	NPS: Medical Consequences Associated with Their Intake. <i>Current Topics in Behavioral Neurosciences</i> , 2017 , 32, 351-380	3.4	21
62	'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports. <i>Current Neuropharmacology</i> , 2020 , 18, 809-837	7.6	21
61	Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 598-609	2.6	21
60	Anabolic androgenic steroid abuse in the United Kingdom: An update. <i>British Journal of Pharmacology</i> , 2020 , 177, 2180-2198	8.6	20
59	Substance-related exogenous psychosis: a postmodern syndrome. <i>CNS Spectrums</i> , 2021 , 26, 84-91	1.8	20
58	Substance-related psychopathology and aggressiveness in a nightlife holiday resort: Results from a pilot study in a psychiatric inpatient unit in Ibiza. <i>Human Psychopharmacology</i> , 2017 , 32, e2586	2.3	18
57	Is There a Potential of Misuse for Venlafaxine and Bupropion?. <i>Frontiers in Pharmacology</i> , 2018 , 9, 239	5.6	18
56	Pregabalin: A range of misuse-related unanswered questions. <i>CNS Neuroscience and Therapeutics</i> , 2019 , 25, 659-660	6.8	17
55	Deaths in the Lesbian, Gay, Bisexual and Transgender United Kingdom Communities Associated with GHB and Precursors. <i>Current Drug Metabolism</i> , 2018 , 19, 1086-1099	3.5	17
54	Role of patient-reported outcomes and other efficacy endpoints in the drug approval process in Europe (2008-2012). <i>Journal of Epidemiology and Global Health</i> , 2015 , 5, 385-95	5.5	16
53	β ₂ Agonists as Misusing Drugs? Assessment of both Clenbuterol- and Salbutamol-related European Medicines Agency Pharmacovigilance Database Reports. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018 , 123, 182-187	3.1	16
52	Evolutionary Considerations on the Emerging Subculture of the E-psychonauts and the Novel Psychoactive Substances: A Comeback to the Shamanism?. <i>Current Neuropharmacology</i> , 2017 , 15, 731-737	7.6	14
51	Novel Opioids: Systematic Web Crawling Within the e-Psychonauts' Scenario. <i>Frontiers in Neuroscience</i> , 2020 , 14, 149	5.1	13
50	How deaths can help clinicians and policy-makers understand the risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 482-498	3.8	13
49	The Use and Impact of Cognitive Enhancers among University Students: A Systematic Review. <i>Brain Sciences</i> , 2021 , 11,	3.4	13
48	4,4'-Dimethylaminorex ("4,4'-DMAR"; "Serotoni") misuse: A Web-based study. <i>Human Psychopharmacology</i> , 2017 , 32, e2575	2.3	12
47	Identifying New/Emerging Psychoactive Substances at the Time of COVID-19; A Web-Based Approach. <i>Frontiers in Psychiatry</i> , 2020 , 11, 632405	5	11

46	The potential utility of some legal highs in CNS disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016 , 64, 267-74	5.5	10
45	Focus on Clozapine Withdrawal- and Misuse-Related Cases as Reported to the European Medicines Agency (EMA) Pharmacovigilance Database. <i>Brain Sciences</i> , 2020 , 10,	3.4	10
44	Venlafaxine as the 'baby ecstasy'? Literature overview and analysis of web-based misusers' experiences. <i>Human Psychopharmacology</i> , 2015 , 30, 255-61	2.3	10
43	Is there a Teratogenicity Risk Associated with Cannabis and Synthetic Cannabimimetics' ('Spice') Intake?. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017 , 16, 585-591	2.6	10
42	Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice. <i>Frontiers in Psychiatry</i> , 2018 , 9, 575	5	10
41	A matter of life and death: substance-caused and substance-related fatalities in Ibiza in 2015. <i>Human Psychopharmacology</i> , 2017 , 32, e2592	2.3	9
40	Is there a potential of misuse for Magnolia officinalis compounds/metabolites?. <i>Human Psychopharmacology</i> , 2017 , 32, e2595	2.3	9
39	The consequences of drug misuse on post-marketing surveillance. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 867-71	3.8	9
38	Exploration of the Use of New Psychoactive Substances by Individuals in Treatment for Substance Misuse in the UK. <i>Brain Sciences</i> , 2018 , 8,	3.4	9
37	The Psychonauts' World of Cognitive Enhancers. <i>Frontiers in Psychiatry</i> , 2020 , 11, 546796	5	9
36	Focus on Over-the-Counter Drugs' Misuse: A Systematic Review on Antihistamines, Cough Medicines, and Decongestants. <i>Frontiers in Psychiatry</i> , 2021 , 12, 657397	5	9
35	New psychoactive substances (NPS) and serotonin syndrome onset: A systematic review. <i>Experimental Neurology</i> , 2021 , 339, 113638	5.7	9
34	The Bridge Between Classical and "Synthetic"/Chemical Psychoses: Towards a Clinical, Psychopathological, and Therapeutic Perspective. <i>Frontiers in Psychiatry</i> , 2019 , 10, 851	5	9
33	The use of new psychoactive substances (NPS) in young people and their role in mental health care: a systematic review. <i>Expert Review of Neurotherapeutics</i> , 2019 , 19, 1253-1264	4.3	8
32	Psychedelic Fauna for Psychonaut Hunters: A Mini-Review. <i>Frontiers in Psychiatry</i> , 2018 , 9, 153	5	8
31	The e-Psychonauts' 'Spiced' World; Assessment of the Synthetic Cannabinoids' Information Available Online. <i>Current Neuropharmacology</i> , 2020 , 18, 966-1051	7.6	8
30	New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues. <i>Current Addiction Reports</i> , 2019 , 6, 140-152	3.9	7
29	Impact of an 18-month, NHS-based, treatment exposure for heroin dependence: results from the London Area Treat 2000 Study. <i>American Journal on Addictions</i> , 2012 , 21, 268-73	3.7	7

28	Is urbanization a risk factor for substance misuse?. <i>Current Opinion in Psychiatry</i> , 2008 , 21, 391-7	4.9	7
27	Quetiapine Abuse Fourteen Years Later: Where Are We Now? A Systematic Review. <i>Substance Use and Misuse</i> , 2020 , 55, 304-313	2.2	7
26	Availability of Illegal Drugs During the COVID-19 Pandemic in Western Germany. <i>Frontiers in Psychiatry</i> , 2021 , 12, 648273	5	6
25	Impact of the UK Psychoactive Substances Act on awareness, use, experiences and knowledge of potential associated health risks of novel psychoactive substances. <i>British Journal of Clinical Pharmacology</i> , 2020 , 86, 505-516	3.8	6
24	Piloting the UK's First Home-Office-Licensed Pharmacist-Led Drug Checking Service at a Community Substance Misuse Service. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2020 , 10,	2.3	5
23	Case Report: Treatment of Kratom Use Disorder With a Classical Tricyclic Antidepressant. <i>Frontiers in Psychiatry</i> , 2021 , 12, 640218	5	5
22	Beyond the 'purple drank': Study of promethazine abuse according to the European Medicines Agency adverse drug reaction reports. <i>Journal of Psychopharmacology</i> , 2021 , 35, 681-692	4.6	5
21	Psychonauts' psychedelics: A systematic, multilingual, web-crawling exercise. <i>European Neuropsychopharmacology</i> , 2021 , 49, 69-92	1.2	5
20	Exploring the Baseline Knowledge and Experience of Healthcare Professionals in the United Kingdom on Novel Psychoactive Substances. <i>Brain Sciences</i> , 2020 , 10,	3.4	4
19	What About Drug Checking? Systematic Review and Netnographic Analysis of Social Media. <i>Current Neuropharmacology</i> , 2020 , 18, 906-917	7.6	4
18	Club Drugs: Psychotropic Effects and Psychopathological Characteristics of a Sample of Inpatients. <i>Frontiers in Psychiatry</i> , 2020 , 11, 879	5	4
17	The e-psychonaut drugs' psychopharmacology. <i>Current Opinion in Pharmacology</i> , 2021 , 57, 165-174	5.1	4
16	Drug Abuse: Treatment and Management 2011 , 53-74		3
15	Prescription Drug Misuse in "Clubbers" and Disco Goers in Ibiza. <i>Frontiers in Psychiatry</i> , 2020 , 11, 5925945		3
14	Is the Urine Cannabinoid Level Measured via a Commercial Point-of-Care Semiquantitative Immunoassay a Cannabis Withdrawal Syndrome Severity Predictor?. <i>Frontiers in Psychiatry</i> , 2020 , 11, 598150	5	2
13	New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature. <i>Medicina (Lithuania)</i> , 2021 , 57,	3.1	2
12	The Psychonauts' Benzodiazepines; Quantitative Structure-Activity Relationship (QSAR) Analysis and Docking Prediction of Their Biological Activity. <i>Pharmaceuticals</i> , 2021 , 14,	5.2	2
11	COVID-19 Pandemic Impact on Substance Misuse: A Social Media Listening, Mixed Method Analysis. <i>Brain Sciences</i> , 2021 , 11,	3.4	2

10	Opioid painkiller dependence in a sample of elderly medical inpatients. <i>Psychogeriatrics</i> , 2021 , 21, 265-271	1.8	2
9	Joint versus separate inpatient rehabilitation treatment for patients with alcohol use disorder or drug use disorder: an observational study. <i>Substance Abuse and Rehabilitation</i> , 2018 , 9, 23-29	5.5	1
8	Assessing prevalence, knowledge and use of cognitive enhancers among university students in the United Arab Emirates: A quantitative study.. <i>PLoS ONE</i> , 2022 , 17, e0262704	3.7	1
7	Use of benzylglycinamide by a HIV-seropositive polysubstance user: The changing pattern of novel psychoactive substance use among youths. <i>Addictive Behaviors</i> , 2016 , 60, 53-7	4.2	1
6	Is medicinal ketamine associated with urinary dysfunction issues? Assessment of both the European Medicines Agency (EMA) and the UK Yellow Card Scheme pharmacovigilance database-related reports. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2021 , 13, 230-237	1.9	1
5	Worsening of the Toxic Effects of (±)-4,4'-DMAR Following Its Co-Administration with (±)-4,4'-DMAR: Neuro-Behavioural, Physiological, Immunohistochemical and Metabolic Studies in Mice. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	1
4	A Focus on Abuse/Misuse and Withdrawal Issues with Selective Serotonin Reuptake Inhibitors (SSRIs): Analysis of Both the European EMA and the US FAERS Pharmacovigilance Databases. <i>Pharmaceuticals</i> , 2022 , 15, 565	5.2	0
3	Pharmacovigilance Signals of the Opioid Epidemic over 10 Years: Data Mining Methods in the Analysis of Pharmacovigilance Datasets Collecting Adverse Drug Reactions (ADRs) Reported to EudraVigilance (EV) and the FDA Adverse Event Reporting System (FAERS). <i>Pharmaceuticals</i> , 2022 , 15, 675	5.2	0
2	Recreational Drugs' Scenario and Compulsory Treatment in the United Kingdom. <i>International Journal of Mental Health</i> , 2008 , 37, 22-56	1.4	
1	Knowledge and Use of Novel Psychoactive Substances in Italy: a Survey-Based Study in the General Population. <i>International Journal of Mental Health and Addiction</i> , 1	8.8	